• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2012 Basque Office for Health Technology Assessment (OSTEBA) [Contaminants from the treatment of drinking water in the Autonomous Community of the Basque Country: Assessment of the risk and alternative treatments]
2012 Basque Office for Health Technology Assessment (OSTEBA) [Cost evaluation of the early breast cancer detection programme of the Autonomous Community of the Basque Country]
2012 Basque Office for Health Technology Assessment (OSTEBA) [Therapeutic strategies in refractory schizophrenia or treatment resistant schizophrenia]
2012 Basque Office for Health Technology Assessment (OSTEBA) [Validation of a malnutrition screening tool useful in a general hospital]
2012 Basque Office for Health Technology Assessment (OSTEBA) [Telemonitoring in patients with heart failure or chronic obstructive disease. Systematic review of the literature]
2012 Basque Office for Health Technology Assessment (OSTEBA) [Budget impact analysis of a telemedicine procedure in quality assurance programs for spirometry in patients with COPD]
2012 Basque Office for Health Technology Assessment (OSTEBA) [Diagnosis and consumption of drugs for Alzheimer's disease in the Basque country]
2012 Basque Office for Health Technology Assessment (OSTEBA) [Systematic review of economic evaluations of dabigatran for stroke prevention in atrial fibrilation]
2012 Health Sciences Institute in Aragon (IACS) Programme activities for early detection of health problems between 0 and 14 years old. Effectiveness, safety and economic evaluation of the different alternatives in the early detection of hip dysplasia in newborns
2012 Adelaide Health Technology Assessment (AHTA) Review of MBS Items for specific ophthalmology services under the MBS Quality Framework (stage II)
2012 Basque Office for Health Technology Assessment (OSTEBA) [Assistance at normal childbirth. Guide for pregnant women, future parents, as well as their partners and relatives]
2012 Basque Office for Health Technology Assessment (OSTEBA) [Clinical practice guideline on type 1 diabetes]
2012 Basque Office for Health Technology Assessment (OSTEBA) [They just told me I have diabetes! Guide for youth and adults with type 1 diabetes and in intensive treatment]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabazitaxel - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Telaprevir - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Microbial collagenase from Clostridium histolyticum - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Retigabine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aliskiren / Amlodipine (combination of active ingredients) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tafamidis - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Positron emission tomography (PET) in ovarian cancer]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/rilpivirine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belatacept -Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rilpivirine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belimumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fampridine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ipilimumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Treatment of obesity in patients with diabetes mellitus type 2 - Guideline synopsis and additional search for and assessment of systematic reviews]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Literature search and evidence assessment to examine the effects of regulations for minimum volumes (acc. to §6 [5], line 2 of the directive on outpatient treatment in hospitals acc. to §116b Social Code Book V) - Rapid report]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vemurafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vandetanib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Benefit assessment of long-term lowering of blood pressure to levels in the lower normal range in patients with diabetes mellitus - Rapid report]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/rilpivirine/tenofovir disoproxil - Addendum to the benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tiotropium bromide in the treatment of chronic obstructive pulmonary disease]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Antibody-eluting stents for treatment of coronary artery stenosis in patients with high risk of restenosis - rapid report]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Antibody-eluting stents for treatment of coronary artery stenosis in patients with high risk of restenosis - rapid report]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Information, consent and medical counselling on ultrasound screening in pregnancy]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Positron emission tomography (PET) in recurrent colorectal cancer]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Primary prevention and health promotion in men]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pasireotide - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor - Assessment according to § 35a (1), Sentence 10, Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Linagliptin - Re-assessment of benefit according to § 35a, Para. 5b, Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ruxolitinib - Assessment according to § 35a (para. 1., sentence 10) Social Code Book V]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Perampanel - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Positron emission tomography (PET) in bone and soft tissue tumors]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aclidinium bromide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axitinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Microbial sealant to reduce surgical site infections following coronary artery bypass graft
2012 National Institute for Health and Care Excellence (NICE) Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy. NICE technology appraisal guidance 242
2012 National Institute for Health and Care Excellence (NICE) Rituximab for the first-line treatment of stage III-IV follicular lymphoma. NICE technology appraisal guidance 243
2012 National Institute for Health and Care Excellence (NICE) Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults. NICE technology appraisal guidance 245
2012 National Institute for Health and Care Excellence (NICE) Pharmalgen for the treatment of bee and wasp venom allergy. NICE technology appraisal guidance 246
2012 National Institute for Health and Care Excellence (NICE) Tocilizumab for the treatment of rheumatoid arthritis. NICE technology appraisal guidance 247
2012 National Institute for Health and Care Excellence (NICE) Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 254
2012 National Institute for Health and Care Excellence (NICE) Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. NICE technology appraisal guidance 256
2012 National Institute for Health and Care Excellence (NICE) Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2. NICE technology appraisal guidance 257
2012 National Institute for Health and Care Excellence (NICE) Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer. NICE technology appraisal guidance 258
2012 National Institute for Health and Care Excellence (NICE) Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. NICE technology appraisal guidance 259
2012 National Institute for Health and Care Excellence (NICE) Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. NICE technology appraisal guidance 260
2012 National Institute for Health and Care Excellence (NICE) Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. NICE technology appraisal guidance 261
2012 National Institute for Health and Care Excellence (NICE) Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer. NICE technology appraisal guidance 263
2012 National Institute for Health and Care Excellence (NICE) Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours. NICE technology appraisal guidance 265
2012 National Institute for Health and Care Excellence (NICE) Mannitol dry powder for inhalation for treating cystic fibrosis. NICE technology appraisal guidance 266
2012 National Institute for Health and Care Excellence (NICE) Ivabradine for treating chronic heart failure. NICE technology appraisal guidance 267
2012 National Institute for Health and Care Excellence (NICE) Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma. NICE technology appraisal guidance 268
2012 National Institute for Health and Care Excellence (NICE) Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma. NICE technology appraisal guidance 269
2012 National Institute for Health and Care Excellence (NICE) Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal). NICE technology appraisal guidance 270
2012 National Institute for Health and Care Excellence (NICE) Laparoscopic gastric plication for the treatment of severe obesity. NICE interventional procedures guidance 432
2012 National Institute for Health and Care Excellence (NICE) Percutaneous laser atherectomy as an adjunct to balloon angioplasty (with or without stenting) for peripheral arterial disease. NICE interventional procedures guidance 433
2012 National Institute for Health and Care Excellence (NICE) Radiofrequency cold ablation for respiratory papillomatosis. NICE interventional procedures guidance 434
2012 National Institute for Health and Care Excellence (NICE) Endovascular stent insertion for intracranial atherosclerotic disease. NICE interventional procedures guidance 429
2012 National Institute for Health and Care Excellence (NICE) Partial replacement of the meniscus of the knee using a biodegradable scaffold. NICE interventional procedures guidance 430
2012 National Institute for Health and Care Excellence (NICE) Percutaneous balloon cryoablation for pulmonary vein isolation in atrial fibrillation. NICE interventional procedures guidance 427
2012 National Institute for Health and Care Excellence (NICE) Focal therapy using cryoablation for localised prostate cancer. NICE interventional procedures guidance 423
2012 National Institute for Health and Care Excellence (NICE) Micropressure therapy for refractory Ménière's disease. NICE interventional procedures guidance 426
2012 National Institute for Health and Care Excellence (NICE) Incisionless otoplasty. NICE interventional procedures guidance 422
2012 National Institute for Health and Care Excellence (NICE) Breast reconstruction using lipomodelling after breast cancer treatment. NICE interventional procedures guidance 417
2012 National Institute for Health and Care Excellence (NICE) PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites. NICE medical technologies guidance 9
2012 National Institute for Health and Care Excellence (NICE) Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms. NICE medical technologies guidance 10
2012 National Institute for Health and Care Excellence (NICE) Mega Soft Patient Return Electrode for use during monopolar electrosurgery. NICE medical technologies guidance 11
2012 National Institute for Health and Care Excellence (NICE) New generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners. NICE diagnostics guidance 3
2012 National Institute for Health and Care Excellence (NICE) Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M. NICE diagnostics guidance 6
2012 National Institute for Health and Care Excellence (NICE) SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver. NICE diagnostics guidance 5
2012 Canary Health Service [Cost-effectiveness of expanded newborn screening by mass spectrometry]
2012 Canary Health Service [Cost-effectiveness of newborn screening for cystic fibrosis]
2012 Canary Health Service [Effectiveness and cost-effectiveness of different pertussis immunization strategies to reduce infant morbidity and mortality]
2012 Canary Health Service [Effectiveness and cost-effectiveness of determining abeta-42, total tau, and phosphorylated tau proteins in cerebrospinal fluid as biomarkers for Alzheimer's disease]
2012 Canary Health Service [Efficacy and cost-effectiveness of cardiac rehabilitation in patients with ischemic heart disease in the outpatient setting (update)]
2012 Canary Health Service [Effectiveness and safety of endovascular procedures in thoracic aortic diseases]
2012 Canary Health Service [Systematic review of the economic impact of MRI-guided surgery (update)]
2012 Canary Health Service [Effectiveness, safety and efficiency of drug-coated stents]
2012 Canary Health Service [Therapeutic management of retinitis pigmentosa]
2012 Canary Health Service [Organisational models in cancer pain management]
2011 NIHR Health Technology Assessment programme A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines (ELEVATE study)
2011 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Literature review of organisational and patient aspects in HTA]
2011 German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Benefit assessment of HPV testing in primary screening for cervical cancer]